The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial

Journal article


Publication Details

Author(s): Hadji P, Stoetzer O, Decker T, Kurbacher CM, Marme F, Schneeweiss A, Mundhenke C, Distelrath A, Fasching P, Lux MP, Lueftner D, Janni W, Muth M, Kreuzeder J, Quiering C, Grischke EM, Tesch H
Journal: Journal of Bone Oncology
Publication year: 2019
Volume: 14
ISSN: 2212-1374


Abstract

Background: Breast cancer and its treatments are associated with a detrimental effect on bone health. Here we report the results of an exploratory analysis assessing changes in levels of biomarkers of bone metabolism in patients enrolled in the phase IIIb 4EVER study.


FAU Authors / FAU Editors

Fasching, Peter PD Dr.
Professur für Translationale Frauenheilkunde und Geburtshilfe


External institutions
Centrum für Hämatologie und Onkologie Bethanien
Charité - Universitätsmedizin Berlin
Deutsches Krebsforschungszentrum (DKFZ)
Eberhard Karls Universität Tübingen
Facharztzentrum am Meer
Krankenhaus Nordwest
Novartis AG
Universitätsklinikum Heidelberg
Universitätsklinikum Schleswig-Holstein (UKSH)
Universitätsklinikum Ulm


How to cite

APA:
Hadji, P., Stoetzer, O., Decker, T., Kurbacher, C.M., Marme, F., Schneeweiss, A.,... Tesch, H. (2019). The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial. Journal of Bone Oncology, 14. https://dx.doi.org/10.1016/j.jbo.2018.09.010

MLA:
Hadji, Peyman, et al. "The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial." Journal of Bone Oncology 14 (2019).

BibTeX: 

Last updated on 2019-22-03 at 09:53